{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:28:34Z","timestamp":1793312914255,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370153"],"award-info":[{"award-number":["82370153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370153"],"award-info":[{"award-number":["82370153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Department of Science and Technology of Jilin Province","award":["YDZJ202201ZYTS606"],"award-info":[{"award-number":["YDZJ202201ZYTS606"]}]},{"name":"the Department of Science and Technology of Jilin Province","award":["YDZJ202201ZYTS606"],"award-info":[{"award-number":["YDZJ202201ZYTS606"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00277-025-06671-w","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T04:19:13Z","timestamp":1759983553000},"page":"4347-4356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of FLT3 mutation on its intracellular localization and implications for anti-leukemia strategy"],"prefix":"10.1007","volume":"104","author":[{"given":"Fei","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"6671_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2147\/ott.S103790","volume":"10","author":"M-A Hospital","year":"2017","unstructured":"Hospital M-A, Green AS, Maciel TT, Moura IC, Leung AY, Bouscary D, Tamburini J (2017) FLT3 inhibitors: clinical potential in acute myeloid leukemia. OncoTargets Ther 10:607\u2013615. https:\/\/doi.org\/10.2147\/ott.S103790","journal-title":"OncoTargets Ther"},{"key":"6671_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02221-2","author":"K Yamawaki","year":"2021","unstructured":"Yamawaki K, Shiina I, Murata T, Tateyama S, Maekawa Y, Niwa M, Shimonaka M, Okamoto K, Suzuki T, Nishida T, Abe R, Obata Y (2021) FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-021-02221-2","journal-title":"Sci Rep"},{"key":"6671_CR3","doi-asserted-by":"publisher","unstructured":"Bunting KD, Volpe G, Clarke M, Garc\u00eca P, Walton DS, Vegiopoulos A, Del Pozzo W, O\u2019Neill LP, Frampton J, Dumon S (2015) Regulation of the Flt3 gene in Haematopoietic stem and early progenitor cells. PLoS ONE 10(9). https:\/\/doi.org\/10.1371\/journal.pone.0138257","DOI":"10.1371\/journal.pone.0138257"},{"issue":"1","key":"6671_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/16078454.2019.1666219","volume":"24","author":"X Hu","year":"2019","unstructured":"Hu X, Chen F (2019) Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia. Hematology 24(1):651\u2013660. https:\/\/doi.org\/10.1080\/16078454.2019.1666219","journal-title":"Hematology"},{"issue":"2","key":"6671_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s1097-2765(03)00505-7","volume":"13","author":"J Griffith","year":"2004","unstructured":"Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K (2004) The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 13(2):169\u2013178. https:\/\/doi.org\/10.1016\/s1097-2765(03)00505-7","journal-title":"Mol Cell"},{"issue":"2","key":"6671_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1073\/pnas.91.2.459","volume":"91","author":"D Small","year":"1994","unstructured":"Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, Witte L, Burrow C, Ratajczak MZ, Gewirtz AM (1994) STK-1, the human homolog of Flk-2\/Flt-3, is selectively expressed in CD34\u2009+\u2009human bone marrow cells and is involved in the proliferation of early progenitor\/stem cells. Proc Natl Acad Sci U S A 91(2):459\u2013463. https:\/\/doi.org\/10.1073\/pnas.91.2.459","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6472","key":"6671_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/368643a0","volume":"368","author":"C Hannum","year":"1994","unstructured":"Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Kastelein R, Bazan JF, Hudak S, Wagner J, Mattson J, Luh J, Duda G, Martina N, Peterson D, Menon S, Shanafelt A, Muench M, Kelner G, Namikawa R, Rennick D, Roncarolo MG, Zlotnik A, Rosnet O, Dubreuil P, Birnbaum D, Lee F (1994) Ligand for FLT3\/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 368(6472):643\u2013648. https:\/\/doi.org\/10.1038\/368643a0","journal-title":"Nature"},{"issue":"3","key":"6671_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/s0092-8674(00)81469-5","volume":"94","author":"A Weiss","year":"1998","unstructured":"Weiss A, Schlessinger J (1998) Switching signals on or off by receptor dimerization. Cell 94(3):277\u2013280. https:\/\/doi.org\/10.1016\/s0092-8674(00)81469-5","journal-title":"Cell"},{"issue":"5","key":"6671_CR9","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100(5):1532\u20131542. https:\/\/doi.org\/10.1182\/blood-2002-02-0492","journal-title":"Blood"},{"issue":"9","key":"6671_CR10","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nrc1169","volume":"3","author":"DL Stirewalt","year":"2003","unstructured":"Stirewalt DL, Radich JP (2003) The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3(9):650\u2013665. https:\/\/doi.org\/10.1038\/nrc1169","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"6671_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2019","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y (2019) FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci 111(2):312\u2013322. https:\/\/doi.org\/10.1111\/cas.14274","journal-title":"Cancer Sci"},{"issue":"8","key":"6671_CR12","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","volume":"97","author":"Y Yamamoto","year":"2001","unstructured":"Yamamoto Y (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97(8):2434\u20132439. https:\/\/doi.org\/10.1182\/blood.V97.8.2434","journal-title":"Blood"},{"issue":"6","key":"6671_CR13","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.biocel.2004.12.005","volume":"37","author":"A Markovic","year":"2005","unstructured":"Markovic A, MacKenzie KL, Lock RB (2005) FLT-3: a new focus in the understanding of acute leukemia. Int J Biochem Cell Biol 37(6):1168\u20131172. https:\/\/doi.org\/10.1016\/j.biocel.2004.12.005","journal-title":"Int J Biochem Cell Biol"},{"issue":"9","key":"6671_CR14","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/sj.leu.2403099","volume":"17","author":"M Levis","year":"2003","unstructured":"Levis M, Small D (2003) FLT3: itdoes matter in leukemia. Leukemia 17(9):1738\u20131752. https:\/\/doi.org\/10.1038\/sj.leu.2403099","journal-title":"Leukemia"},{"issue":"2","key":"6671_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1182\/blood-2006-06-001149","volume":"109","author":"K Mr\u00f3zek","year":"2006","unstructured":"Mr\u00f3zek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD (2006) Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 109(2):431\u2013448. https:\/\/doi.org\/10.1182\/blood-2006-06-001149","journal-title":"Blood"},{"issue":"12","key":"6671_CR16","doi-asserted-by":"publisher","first-page":"10410","DOI":"10.3390\/curroncol30120759","volume":"30","author":"J Bergeron","year":"2023","unstructured":"Bergeron J, Capo-Chichi J-M, Tsui H, Mahe E, Berardi P, Minden MD, Brandwein JM, Schuh AC (2023) The clinical utility of FLT3 mutation testing in acute leukemia: a Canadian consensus. Curr Oncol 30(12):10410\u201310436. https:\/\/doi.org\/10.3390\/curroncol30120759","journal-title":"Curr Oncol"},{"key":"6671_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep11702","author":"Y-Y Ke","year":"2015","unstructured":"Ke Y-Y, Singh VK, Coumar MS, Hsu YC, Wang W-C, Song J-S, Chen C-H, Lin W-H, Wu S-H, Hsu JTA, Shih C, Hsieh H-P (2015) Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification. Sci Rep. https:\/\/doi.org\/10.1038\/srep11702","journal-title":"Sci Rep"},{"issue":"5","key":"6671_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, D\u00f6hner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, D\u00f6hner H (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with aFLT3Mutation. N Engl J Med 377(5):454\u2013464. https:\/\/doi.org\/10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"},{"issue":"6","key":"6671_CR19","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1182\/blood-2018-01-821629","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie J-P, Martinelli G, Kantarjian HM, Levis MJ (2018) Phase 2b study of 2 dosing regimens of Quizartinib monotherapy in FLT3-ITD\u2013mutated, relapsed or refractory AML. Blood 132(6):598\u2013607. https:\/\/doi.org\/10.1182\/blood-2018-01-821629","journal-title":"Blood"},{"issue":"23","key":"6671_CR20","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1182\/blood.2021011583","volume":"139","author":"AE Perl","year":"2022","unstructured":"Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, R\u00e9cher C, Yoon S-S, Hosono N, Onozawa M, Chiba S, Kim H-J, Hasabou N, Lu Q, Tiu R, Levis MJ (2022) Follow-up of patients with R\/R FLT3-mutation\u2013positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 139(23):3366\u20133375. https:\/\/doi.org\/10.1182\/blood.2021011583","journal-title":"Blood"},{"issue":"3","key":"6671_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.drup.2009.04.001","volume":"12","author":"E Weisberg","year":"2009","unstructured":"Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD (2009) FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 12(3):81\u201389. https:\/\/doi.org\/10.1016\/j.drup.2009.04.001","journal-title":"Drug Resist Updat"},{"key":"6671_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112493","author":"S Scholl","year":"2020","unstructured":"Scholl S, Fleischmann M, Schnetzke U, Heidel FH (2020) Molecular mechanisms of resistance to FLT3 inhibitors in acute myeloid leukemia: ongoing challenges and future treatments. Cells. https:\/\/doi.org\/10.3390\/cells9112493","journal-title":"Cells"},{"issue":"12","key":"6671_CR23","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","volume":"96","author":"M Mizuki","year":"2000","unstructured":"Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, M\u00fcller C, Gr\u00fcning W, Kratz-Albers K, Serve S, Steur C, B\u00fcchner T, Kienast J, Kanakura Y, Berdel WE, Serve H (2000) Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96(12):3907\u20133914. https:\/\/doi.org\/10.1182\/blood.V96.12.3907","journal-title":"Blood"},{"issue":"14","key":"6671_CR24","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1158\/1078-0432.Ccr-07-1873","volume":"14","author":"S Vempati","year":"2008","unstructured":"Vempati S, Reindl C, Wolf U, Kern R, Petropoulos K, Naidu VM, Buske C, Hiddemann W, Kohl TM, Spiekermann K (2008) Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591. Clin Cancer Res 14(14):4437\u20134445. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-1873","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6671_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2004-07-2942","volume":"106","author":"C Choudhary","year":"2005","unstructured":"Choudhary C, Schw\u00e4ble J, Brandts C, Tickenbrock L, Sargin Bl, Kindler T, Fischer T, Berdel WE, M\u00fcller-Tidow C, Serve H (2005) AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 106(1):265\u2013273. https:\/\/doi.org\/10.1182\/blood-2004-07-2942","journal-title":"Blood"},{"key":"6671_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.leukres.2016.11.006","volume":"52","author":"JN Moloney","year":"2017","unstructured":"Moloney JN, Stanicka J, Cotter TG (2017) Subcellular localization of the FLT3-ITD oncogene plays a significant role in the production of NOX- and p22phox-derived reactive oxygen species in acute myeloid leukemia. Leuk Res 52:34\u201342. https:\/\/doi.org\/10.1016\/j.leukres.2016.11.006","journal-title":"Leuk Res"},{"issue":"9","key":"6671_CR27","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1128\/mcb.25.9.3690-3703.2005","volume":"25","author":"D-E Schmidt-Arras","year":"2023","unstructured":"Schmidt-Arras D-E, B\u00f6hmer A, Markova B, Choudhary C, Serve H, B\u00f6hmer F-D (2023) Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases. Mol Cell Biol 25(9):3690\u20133703. https:\/\/doi.org\/10.1128\/mcb.25.9.3690-3703.2005","journal-title":"Mol Cell Biol"},{"issue":"1\u20132","key":"6671_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000118788","volume":"188","author":"S Koch","year":"2008","unstructured":"Koch S, Jacobi A, Ryser M, Ehninger G, Thiede C (2008) Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis. Cells Tissues Organs 188(1\u20132):225\u2013235. https:\/\/doi.org\/10.1159\/000118788","journal-title":"Cells Tissues Organs"},{"issue":"15","key":"6671_CR29","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1182\/blood-2007-10-121426","volume":"113","author":"D Schmidt-Arras","year":"2009","unstructured":"Schmidt-Arras D, B\u00f6hmer S-A, Koch S, M\u00fcller JP, Blei L, Cornils H, Bauer R, Korasikha S, Thiede C, B\u00f6hmer F-D (2009) Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality. Blood 113(15):3568\u20133576. https:\/\/doi.org\/10.1182\/blood-2007-10-121426","journal-title":"Blood"},{"issue":"2","key":"6671_CR30","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1006\/bbrc.1998.9959","volume":"254","author":"S Zhang","year":"1999","unstructured":"Zhang S, Broxmeyer HE (1999) P85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells. Biochem Biophys Res Commun 254(2):440\u2013445. https:\/\/doi.org\/10.1006\/bbrc.1998.9959","journal-title":"Biochem Biophys Res Commun"},{"issue":"22","key":"6671_CR31","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1182\/blood.2021011582","volume":"138","author":"K Lv","year":"2021","unstructured":"Lv K, Ren J-G, Han X, Gui J, Gong C, Tong W (2021) Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression. Blood 138(22):2244\u20132255. https:\/\/doi.org\/10.1182\/blood.2021011582","journal-title":"Blood"},{"key":"6671_CR32","doi-asserted-by":"publisher","unstructured":"Vasconcelos-dos-Santos A, Oliveira IA, Lucena MC, Mantuano NR, Whelan SA, Dias WB, Todeschini AR (2015) Biosynthetic machinery involved in aberrant glycosylation: promising targets for developing of drugs against cancer. Front Oncol 5. https:\/\/doi.org\/10.3389\/fonc.2015.00138","DOI":"10.3389\/fonc.2015.00138"},{"issue":"6","key":"6671_CR33","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/j.1440-1746.1998.tb00699.x","volume":"13","author":"S Mori","year":"2008","unstructured":"Mori S, Aoyagi Y, Yanagi M, Suzuki Y, Asakura H (2008) Serum N-acetylglucosaminyltransferase III activities in hepatocellular carcinoma. J Gastroenterol Hepatol 13(6):610\u2013619. https:\/\/doi.org\/10.1111\/j.1440-1746.1998.tb00699.x","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"6671_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nrd1751","volume":"4","author":"DH Dube","year":"2005","unstructured":"Dube DH, Bertozzi CR (2005) Glycans in cancer and inflammation \u2014 potential for therapeutics and diagnostics. Nat Rev Drug Discov 4(6):477\u2013488. https:\/\/doi.org\/10.1038\/nrd1751","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"6671_CR35","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.molcel.2009.09.019","volume":"36","author":"C Choudhary","year":"2009","unstructured":"Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PNG, B\u00f6hmer FD, Gerke V, Schmidt-Arras D-E, Berdel WE, M\u00fcller-Tidow C, Mann M, Serve H (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36(2):326\u2013339. https:\/\/doi.org\/10.1016\/j.molcel.2009.09.019","journal-title":"Mol Cell"},{"key":"6671_CR36","doi-asserted-by":"publisher","unstructured":"Bunting KD, Natarajan K, Xie Y, Burcu M, Linn DE, Qiu Y, Baer MR (2013) Pim-1 Kinase Phosphorylates and Stabilizes 130\u00a0kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication. PLoS ONE 8(9). https:\/\/doi.org\/10.1371\/journal.pone.0074653","DOI":"10.1371\/journal.pone.0074653"},{"key":"6671_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221810040","author":"A Hindley","year":"2021","unstructured":"Hindley A, Catherwood MA, McMullin MF, Mills KI (2021) Significance of NPM1 gene mutations in AML. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms221810040","journal-title":"Int J Mol Sci"},{"issue":"19","key":"6671_CR38","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/bloodadvances.2017009019","volume":"1","author":"P Boddu","year":"2017","unstructured":"Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver N, Pierce S, Andreeff M, Ravandi F, Cortes J, Kornblau SM (2017) Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv 1(19):1546\u20131550. https:\/\/doi.org\/10.1182\/bloodadvances.2017009019","journal-title":"Blood Adv"},{"issue":"4","key":"6671_CR39","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1182\/blood.2018883140","volume":"134","author":"A Rudorf","year":"2019","unstructured":"Rudorf A, M\u00fcller TA, Klingeberg C, Kreutmair S, Poggio T, Gorantla SP, R\u00fcckert T, Schmitt-Graeff A, Gengenbacher A, Paschka P, Baldus C, Zeiser R, Vassiliou GS, Bradley A, Duyster J, Illert AL (2019) NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia. Blood 134(4):383\u2013388. https:\/\/doi.org\/10.1182\/blood.2018883140","journal-title":"Blood"},{"key":"6671_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2011.07.009","volume":"1808","author":"C Aicart-Ramos","year":"2011","unstructured":"Aicart-Ramos C, Valero RA, Rodriguez-Crespo I (2011) Protein palmitoylation and subcellular trafficking. Biochimica et biophysica acta (BBA) - Biomembranes 1808:122981\u20132994. https:\/\/doi.org\/10.1016\/j.bbamem.2011.07.009","journal-title":"Biochimica et biophysica acta (BBA) - Biomembranes"},{"issue":"3","key":"6671_CR41","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1083\/jcb.200601051","volume":"174","author":"C Fern\u00e1ndez-Hernando","year":"2006","unstructured":"Fern\u00e1ndez-Hernando C, Fukata M, Bernatchez PN, Fukata Y, Lin MI, Bredt DS, Sessa WC (2006) Identification of Golgi-localized acyl transferases that palmitoylate and regulate endothelial nitric oxide synthase. J Cell Biol 174(3):369\u2013377. https:\/\/doi.org\/10.1083\/jcb.200601051","journal-title":"J Cell Biol"},{"issue":"3","key":"6671_CR42","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.molcel.2016.04.003","volume":"62","author":"KristinB Runkle","year":"2016","unstructured":"Runkle Kristin B, Kharbanda A, Stypulkowski E, Cao X-J, Wang W, Garcia Benjamin A, Witze Eric S (2016) Inhibition of DHHC20-mediated EGFR palmitoylation creates a dependence on EGFR signaling. Mol Cell 62(3):385\u2013396. https:\/\/doi.org\/10.1016\/j.molcel.2016.04.003","journal-title":"Mol Cell"},{"key":"6671_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aax2364","author":"A Kharbanda","year":"2020","unstructured":"Kharbanda A, Walter DM, Gudiel AA, Schek N, Feldser DM, Witze ES (2020) Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis. Sci Signal. https:\/\/doi.org\/10.1126\/scisignal.aax2364","journal-title":"Sci Signal"},{"key":"6671_CR44","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.210033","author":"YA Kadry","year":"2021","unstructured":"Kadry YA, Lee J-Y, Witze ES (2021) Regulation of EGFR signalling by palmitoylation and its role in tumorigenesis. Open Biol. https:\/\/doi.org\/10.1098\/rsob.210033","journal-title":"Open Biol"},{"issue":"12","key":"6671_CR45","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/leu.2013.83","volume":"27","author":"A Caldarelli","year":"2013","unstructured":"Caldarelli A, M\u00fcller JP, Paskowski-Rogacz M, Herrmann K, Bauer R, Koch S, Heninger AK, Krastev D, Ding L, Kasper S, Fischer T, Brodhun M, B\u00f6hmer FD, Buchholz F (2013) A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling. Leukemia 27(12):2301\u20132310. https:\/\/doi.org\/10.1038\/leu.2013.83","journal-title":"Leukemia"},{"key":"6671_CR46","doi-asserted-by":"publisher","unstructured":"K\u00f6the S, M\u00fcller JP, B\u00f6hmer S-A, Tschongov T, Fricke M, Koch S, Thiede C, Requardt RP, Rubio I, B\u00f6hmer FD (2013) Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals via K-Ras at the plasma membrane of acute myeloid leukemia cells. J Cell Sci 4746\u20134755. https:\/\/doi.org\/10.1242\/jcs.131789","DOI":"10.1242\/jcs.131789"},{"issue":"2","key":"6671_CR47","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/leu.2017.257","volume":"32","author":"K Reiter","year":"2017","unstructured":"Reiter K, Polzer H, Krupka C, Maiser A, Vick B, Rothenberg-Thurley M, Metzeler KH, D\u00f6rfel D, Salih HR, Jung G, N\u00f6\u00dfner E, Jeremias I, Hiddemann W, Leonhardt H, Spiekermann K, Subklewe M, Greif PA (2017) Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. Leukemia 32(2):313\u2013322. https:\/\/doi.org\/10.1038\/leu.2017.257","journal-title":"Leukemia"},{"key":"6671_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112992","author":"M Fleischmann","year":"2021","unstructured":"Fleischmann M, Fischer M, Schnetzke U, Fortner C, Kirkpatrick J, Heidel FH, Hochhaus A, Scholl S (2021) Modulation of FLT3-ITD localization and targeting of distinct downstream signaling pathways as potential strategies to overcome FLT3-inhibitor resistance. Cells. https:\/\/doi.org\/10.3390\/cells10112992","journal-title":"Cells"},{"issue":"10","key":"6671_CR49","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1158\/1535-7163.Mct-15-0163","volume":"14","author":"C Larrue","year":"2015","unstructured":"Larrue C, Saland E, Vergez F, Serhan N, Delabesse E, Mansat-De Mas V, Hospital M-A, Tamburini J, Manenti S, Sarry JE, R\u00e9cher C (2015) Antileukemic activity of 2-Deoxy-d-glucose through inhibition of N-linked glycosylation in acute myeloid leukemia with FLT3-ITD or c-KIT mutations. Mol Cancer Ther 14(10):2364\u20132373. https:\/\/doi.org\/10.1158\/1535-7163.Mct-15-0163","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"6671_CR50","doi-asserted-by":"publisher","first-page":"26613","DOI":"10.18632\/oncotarget.15772","volume":"8","author":"D Tsitsipatis","year":"2017","unstructured":"Tsitsipatis D, Jayavelu AK, M\u00fcller JP, Bauer R, Schmidt-Arras D, Mahboobi S, Schn\u00f6der TM, Heidel F, B\u00f6hmer F-D (2017) Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation. Oncotarget 8(16):26613\u201326624. https:\/\/doi.org\/10.18632\/oncotarget.15772","journal-title":"Oncotarget"},{"issue":"15","key":"6671_CR51","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/blood-2012-01-403493","volume":"120","author":"AB Williams","year":"2012","unstructured":"Williams AB, Li L, Nguyen B, Brown P, Levis M, Small D (2012) Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3\/ITD leukemia. Blood 120(15):3069\u20133079. https:\/\/doi.org\/10.1182\/blood-2012-01-403493","journal-title":"Blood"},{"issue":"3","key":"6671_CR52","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.bbamcr.2011.10.013","volume":"1823","author":"M Marzec","year":"2012","unstructured":"Marzec M, Eletto D, Argon Y (2012) GRP94: an HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum. Biochimica et Biophysica Acta (BBA) 1823(3):774\u2013787. https:\/\/doi.org\/10.1016\/j.bbamcr.2011.10.013","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"11","key":"6671_CR53","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1093\/jn\/114.11.2097","volume":"114","author":"WL Dills","year":"1984","unstructured":"Dills WL, Kwong E, Covey TR, Nesheim MC (1984) Effects of diets deficient in glucose and glucose precursors on the growth of the walker carcinosarcoma 256 in rats. J Nutr 114(11):2097\u20132106. https:\/\/doi.org\/10.1093\/jn\/114.11.2097","journal-title":"J Nutr"},{"issue":"4","key":"6671_CR54","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00280-010-1391-0","volume":"67","author":"H Xi","year":"2010","unstructured":"Xi H, Kurtoglu M, Liu H, Wangpaichitr M, You M, Liu X, Savaraj N, Lampidis TJ (2010) 2-deoxy-d-glucose activates autophagy via Endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother Pharmacol 67(4):899\u2013910. https:\/\/doi.org\/10.1007\/s00280-010-1391-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"6671_CR55","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1158\/1535-7163.Mct-07-0310","volume":"6","author":"M Kurtoglu","year":"2007","unstructured":"Kurtoglu M, Gao N, Shang J, Maher JC, Lehrman MA, Wangpaichitr M, Savaraj N, Lane AN, Lampidis TJ (2007) Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther 6(11):3049\u20133058. https:\/\/doi.org\/10.1158\/1535-7163.Mct-07-0310","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"6671_CR56","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1038\/leu.2017.45","volume":"31","author":"HQ Ju","year":"2017","unstructured":"Ju HQ, Zhan G, Huang A, Sun Y, Wen S, Yang J, Lu Wh, Xu Rh, Li J, Li Y, Garcia-Manero G, Huang P, Hu Y (2017) ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition. Leukemia 31(10):2143\u20132150. https:\/\/doi.org\/10.1038\/leu.2017.45","journal-title":"Leukemia"},{"issue":"10","key":"6671_CR57","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1021\/bi00513a039","volume":"20","author":"RW Keenan","year":"2002","unstructured":"Keenan RW, Hamill RL, Occolowitz JL, Elbein AD (2002) Biological activities of isolated tunicamycin and streptovirudin fractions. Biochemistry 20(10):2968\u20132973. https:\/\/doi.org\/10.1021\/bi00513a039","journal-title":"Biochemistry"},{"issue":"6","key":"6671_CR58","doi-asserted-by":"publisher","first-page":"337","DOI":"10.14348\/molcells.2023.0001","volume":"46","author":"D Yoon","year":"2023","unstructured":"Yoon D, Moon JH, Cho A, Boo H, Cha JS, Lee Y, Yoo J (2023) Structure-based insight on the mechanism of N-glycosylation inhibition by tunicamycin. Mol Cells 46(6):337\u2013344. https:\/\/doi.org\/10.14348\/molcells.2023.0001","journal-title":"Mol Cells"},{"issue":"36","key":"6671_CR59","doi-asserted-by":"publisher","first-page":"38912","DOI":"10.18632\/oncotarget.5334","volume":"6","author":"X Han","year":"2015","unstructured":"Han X, Zhang X, Li H, Huang S, Zhang S, Wang F, Shi Y (2015) Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo. Oncotarget 6(36):38912\u201338925. https:\/\/doi.org\/10.18632\/oncotarget.5334","journal-title":"Oncotarget"},{"issue":"4","key":"6671_CR60","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00280-017-3393-7","volume":"80","author":"S Huang","year":"2017","unstructured":"Huang S, Wang D, Zhang S, Huang X, Wang D, Ijaz M, Shi Y (2017) Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K\/AKT and MAPK pathways in breast cancer. Cancer Chemother Pharmacol 80(4):685\u2013696. https:\/\/doi.org\/10.1007\/s00280-017-3393-7","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"6671_CR61","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.bcp.2007.04.028","volume":"74","author":"SN Hamadmad","year":"2007","unstructured":"Hamadmad SN, Hohl RJ (2007) Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation. Biochem Pharmacol 74(4):590\u2013600. https:\/\/doi.org\/10.1016\/j.bcp.2007.04.028","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"6671_CR62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/1043-6618(95)80042-5","volume":"31","author":"A Corsini","year":"1995","unstructured":"Corsini A (1995) Pharmacology of competitive inhibitors of HMg-CoA reductase. Pharmacol Res 31(1):9\u201327. https:\/\/doi.org\/10.1016\/1043-6618(95)80042-5","journal-title":"Pharmacol Res"},{"issue":"7","key":"6671_CR63","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/153537020422900701","volume":"229","author":"H Mo","year":"2016","unstructured":"Mo H, Elson CE (2016) Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 229(7):567\u2013585. https:\/\/doi.org\/10.1177\/153537020422900701","journal-title":"Exp Biol Med (Maywood)"},{"issue":"2","key":"6671_CR64","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/s0145-2126(02)00085-1","volume":"27","author":"DL Stirewalt","year":"2003","unstructured":"Stirewalt DL, Appelbaum FR, Willman CL, Zager RA, Banker DE (2003) Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with Ras hotspot mutations or overexpression. Leuk Res 27(2):133\u2013145. https:\/\/doi.org\/10.1016\/s0145-2126(02)00085-1","journal-title":"Leuk Res"},{"issue":"1","key":"6671_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-103","volume":"10","author":"A Martirosyan","year":"2010","unstructured":"Martirosyan A, Clendening JW, Goard CA, Penn LZ (2010) Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer 10(1):103. https:\/\/doi.org\/10.1186\/1471-2407-10-103","journal-title":"BMC Cancer"},{"issue":"2","key":"6671_CR66","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00280-005-0013-8","volume":"57","author":"SA Holstein","year":"2005","unstructured":"Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ (2005) Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 57(2):155\u2013164. https:\/\/doi.org\/10.1007\/s00280-005-0013-8","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"6671_CR67","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1074\/jbc.M112.361709","volume":"288","author":"J Tahvanainen","year":"2013","unstructured":"Tahvanainen J, Kyl\u00e4niemi MK, Kanduri K, Gupta B, L\u00e4hteenm\u00e4ki H, Kallonen T, Rajavuori A, Rasool O, Koskinen PJ, Rao KVS, L\u00e4hdesm\u00e4ki H, Lahesmaa R (2013) Proviral integration site for Moloney murine leukemia virus (PIM) kinases promote human T helper 1 cell differentiation. J Biol Chem 288(5):3048\u20133058. https:\/\/doi.org\/10.1074\/jbc.M112.361709","journal-title":"J Biol Chem"},{"issue":"9","key":"6671_CR68","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1158\/1541-7786.Mcr-06-0388","volume":"5","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Wang Z, Magnuson NS (2007) Pim-1 kinase-dependent phosphorylation of p21Cip1\/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res 5(9):909\u2013922. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-06-0388","journal-title":"Mol Cancer Res"},{"issue":"4","key":"6671_CR69","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1073\/pnas.042035699","volume":"99","author":"XP Chen","year":"2002","unstructured":"Chen XP, Losman JA, Cowan S, Donahue E, Fay S, Vuong BQ, Nawijn MC, Capece D, Cohan VL, Rothman P (2002) Pim serine\/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci U S A 99(4):2175\u20132180. https:\/\/doi.org\/10.1073\/pnas.042035699","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"6671_CR70","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/jcb.21906","volume":"105","author":"HR Kim","year":"2008","unstructured":"Kim HR, Oh BC, Choi JK, Bae SC (2008) Pim-1 kinase phosphorylates and stabilizes RUNX3 and alters its subcellular localization. J Cell Biochem 105(4):1048\u20131058. https:\/\/doi.org\/10.1002\/jcb.21906","journal-title":"J Cell Biochem"},{"issue":"35","key":"6671_CR71","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1038\/onc.2008.123","volume":"27","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Wang Z, Li X, Magnuson NS (2008) Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 27(35):4809\u20134819. https:\/\/doi.org\/10.1038\/onc.2008.123","journal-title":"Oncogene"},{"issue":"2","key":"6671_CR72","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.leukres.2011.07.011","volume":"36","author":"AT Fathi","year":"2012","unstructured":"Fathi AT, Arowojolu O, Swinnen I, Sato T, Rajkhowa T, Small D, Marmsater F, Robinson JE, Gross SD, Martinson M, Allen S, Kallan NC, Levis M (2012) A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. Leuk Res 36(2):224\u2013231. https:\/\/doi.org\/10.1016\/j.leukres.2011.07.011","journal-title":"Leuk Res"},{"issue":"11","key":"6671_CR73","doi-asserted-by":"publisher","first-page":"14381","DOI":"10.1007\/s13277-016-5343-0","volume":"37","author":"YM Hazari","year":"2016","unstructured":"Hazari YM, Bashir A, Haq Eu, Fazili KM (2016) Emerging tale of UPR and cancer: an essentiality for malignancy. Tumor Biol 37(11):14381\u201314390. https:\/\/doi.org\/10.1007\/s13277-016-5343-0","journal-title":"Tumor Biol"},{"key":"6671_CR74","doi-asserted-by":"publisher","unstructured":"Papaioannou A, Chevet E (2017) Driving Cancer Tumorigenesis and Metastasis Through UPR Signaling. In: Coordinating Organismal Physiology Through the Unfolded Protein Response. Current Topics in Microbiology and Immunology. pp 159\u2013192. https:\/\/doi.org\/10.1007\/82_2017_36","DOI":"10.1007\/82_2017_36"},{"issue":"1","key":"6671_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/boc.201800050","volume":"111","author":"E Madden","year":"2018","unstructured":"Madden E, Logue SE, Healy SJ, Manie S, Samali A (2018) The role of the unfolded protein response in cancer progression: from oncogenesis to chemoresistance. Biol Cell 111(1):1\u201317. https:\/\/doi.org\/10.1111\/boc.201800050","journal-title":"Biol Cell"},{"key":"6671_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092560","author":"A Hoter","year":"2018","unstructured":"Hoter A, El-Sabban ME, Naim HY (2018) The HSP90 family: structure, regulation, function, and implications in health and disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19092560","journal-title":"Int J Mol Sci"},{"key":"6671_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1436973","author":"Z Albakova","year":"2024","unstructured":"Albakova Z (2024) HSP90 multi-functionality in cancer. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1436973","journal-title":"Front Immunol"},{"issue":"6709","key":"6671_CR78","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/24550","volume":"396","author":"SL Rutherford","year":"1998","unstructured":"Rutherford SL, Lindquist S (1998) Hsp90 as a capacitor for morphological evolution. Nature 396(6709):336\u2013342. https:\/\/doi.org\/10.1038\/24550","journal-title":"Nature"},{"issue":"3","key":"6671_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/ph15030320","volume":"15","author":"S-Y Han","year":"2022","unstructured":"Han S-Y (2022) Small molecule induced FLT3 degradation. Pharmaceuticals 15(3):320. https:\/\/doi.org\/10.3390\/ph15030320","journal-title":"Pharmaceuticals"},{"issue":"8","key":"6671_CR80","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3727\/096504018x15154104709325","volume":"26","author":"BTK Ly","year":"2018","unstructured":"Ly BTK, Chi HT (2018) ETV6\/FLT3 fusion is a novel client protein of Hsp90. Oncol Res Featuring Preclinical Clin Cancer Ther 26(8):1201\u20131205. https:\/\/doi.org\/10.3727\/096504018x15154104709325","journal-title":"Oncol Res Featuring Preclinical Clin Cancer Ther"},{"issue":"8","key":"6671_CR81","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/sj.leu.2402558","volume":"16","author":"Y Minami","year":"2002","unstructured":"Minami Y, Kiyoi H, Yamamoto Y, Yamamoto K, Ueda R, Saito H, Naoe T (2002) Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia 16(8):1535\u20131540. https:\/\/doi.org\/10.1038\/sj.leu.2402558","journal-title":"Leukemia"},{"issue":"5","key":"6671_CR82","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/s1535-6108(02)00069-7","volume":"1","author":"E Weisberg","year":"2002","unstructured":"Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, Gilliland DG, Griffin JD (2002) Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1(5):433\u2013443. https:\/\/doi.org\/10.1016\/s1535-6108(02)00069-7","journal-title":"Cancer Cell"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06671-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06671-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06671-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:30:19Z","timestamp":1761283819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06671-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":82,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6671"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06671-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}